GSK plc (LSE/NYSE: GSK) announced on 13 November 2026 that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending a label update for Bexsero, its Meningitis B vaccine, to include a single booster dose for individuals aged 10 years and older previously vaccinated at least two years earlier. The recommendation is supported by clinical data showing that immune memory established during infant vaccination can be boosted with one dose up to 19 years later. The development is significant for GSK's vaccines portfolio, as Bexsero is registered in 61 countries and already included in 15 national infant immunisation programmes across Europe.

Key Points

  • GSK plc (LSE/NYSE: GSK) is a global biopharma company headquartered in London
  • CHMP issued a positive opinion recommending Bexsero's label be updated to include a single booster dose for individuals aged 10 and older
  • The Men-B-096 Phase IIIb study enrolled 312 participants across Finland, Italy, Spain and the UK, and met its primary endpoint
  • Investors should watch for European Commission formal approval, which typically follows a positive CHMP opinion, and any subsequent national programme adoption decisions

CHMP Recommendation Supports Single Bexsero Booster Based on 19-Year Immune Memory Data

The CHMP's positive opinion is grounded in data from the Men-B-096 study, a Phase IIIb open-label, multi-centre trial assessing the immune response and safety of a single Bexsero booster dose in healthy individuals aged 10 to 20 years. The study enrolled 312 participants across Finland, Italy, Spain and the United Kingdom, including 234 who had received Bexsero during infancy. Clinical data demonstrated that immune memory established through primary infant vaccination can be effectively boosted with a single dose up to 19 years later. The study met its primary endpoint, and the safety and reactogenicity profile was consistent with Bexsero's established record in this age group.

Adolescent Disease Risk Drives Strategic Rationale for Bexsero Label Expansion

The announcement highlights a well-documented epidemiological pattern underpinning the label update's public health rationale. Invasive Meningococcal Disease incidence is highest in infants and young children but reaches a second peak in adolescents and young adults, a group considered at elevated transmission risk due to close social contact and shared living environments. In Europe, serogroup B is the leading cause of invasive meningococcal disease across all age groups under 65 years, according to the European Centre for Disease Prevention and Control. The positive CHMP opinion, the company states, could support vaccination programmes in maintaining protection precisely as the first generation of Bexsero-vaccinated infants enters this higher-risk adolescent period.

Bexsero's Global Footprint: 61 Countries, 140 Million Doses Distributed Since 2015

Bexsero is already one of GSK's most widely deployed vaccine assets, registered in 61 countries and included in 15 national and regional infant immunisation programmes across Europe, as well as three national adolescent programmes. According to GSK's own data, approximately 140 million doses have been distributed globally since 2015. If the European Commission formally approves the updated label following the CHMP opinion — the standard regulatory pathway — the expanded indication could open an additional market segment targeting adolescents in countries with established infant MenB programmes. The company did not disclose financial projections associated with the label update in the announcement.

Regulatory Pathway and Programme Adoption Remain Key Milestones for GSK Investors

A positive CHMP opinion represents a recommendation rather than a final regulatory decision; formal approval from the European Commission is the next required step. Beyond regulatory approval, actual uptake depends on individual national health authorities choosing to extend or introduce adolescent booster programmes, a process that varies by country and health system. GSK cautioned in the announcement that forward-looking statements are subject to risks and uncertainties, referencing factors detailed in its Annual Report on Form 20-F for 2025 and its Q3 2026 results. Investors monitoring GSK's vaccines segment will likely watch the European Commission's response and any national programme announcements that follow.